Publications by authors named "T A Berezina"
Background: Despite existing evidence of the high predictive value of natriuretic peptides (NPs) in patients with heart failure (HF), patients treated with guideline-directed therapy who have low or near-normal NP levels are unlikely to be correctly stratified for risk of clinical outcomes. The aim of this study is to detect plausible predictors for poor one-year clinical outcomes in patients with HFpEF and low NT-proBNP treated with in accordance with conventional guidelines.
Methods: A total of 337 patients with HF with preserved ejection fraction (HFpEF) who had low levels of N-terminal natriuretic pro-peptide (NT-proBNP) at discharge due to optimal guideline-based therapy were enrolled in the study.
Introduction: Although contrast-induced (CI) acute kidney injury (AKI) is a common complication in high-risk individuals requiring evaluation with contrast-enhanced angiography, the possible predictors of CI-AKI in patients with obesity are not fully understood. The aim of this study was to elucidate plausible factors associated with the irreversibility of CI-AKI in individuals with obesity undergoing contrast-enhanced computed tomography coronary angiography.
Methods: A total of 96 adult patients with obesity and the KDIGO criteria of CI-AKI (increase of serum levels of creatinine ≥ 25% or ≥ 500 µmol/L at 48 h after procedure) were retrospectively screened from the cohort of 1833 patients who underwent iodine contrast medium (ICM)-enhanced computed tomography coronary angiography, and were included in the study.
In patients with type 2 diabetes mellitus (T2DM), asymptomatic adverse cardiac remodeling plays a pivotal role in the development of heart failure (HF). Patients with T2DM often have low or near-normal levels of natriuretic peptides, including N-terminal brain natriuretic peptide (NT-proBNP), which have been inconclusive in predicting the transition from asymptomatic adverse cardiac remodeling to HF with preserved ejection fraction (HFpEF). The aim of this study was to elucidate the predictive ability of adropin for HFpEF depending on the circulating levels of NT-proBNP.
View Article and Find Full Text PDFArticle Synopsis
- Adropin is a multifunctional peptide linked to various health factors, and its lower levels are associated with worse outcomes in cardiovascular and renal diseases, obesity, and diabetes.
- The study specifically investigates adropin as a predictive biomarker for clinical outcomes in post-STEMI patients who are newly diagnosed with prediabetes, enrolling 498 such patients over a 3-year follow-up period.
- Results indicate that serum adropin levels below 2.15 ng/mL significantly predict adverse clinical events, suggesting that low adropin levels can serve as an independent risk factor for worse outcomes in this patient group.
Article Synopsis
- The study examines if irisin can serve as a predictive biomarker for kidney issues in type 2 diabetes (T2DM) patients with undiagnosed heart failure (HF).
- The research involved 146 T2DM patients, tracking their heart and kidney health over 52 weeks, using various cardiac function assessments and blood tests, including levels of irisin and NT-proBNP.
- Findings indicated that low baseline irisin levels (< 4.15 ng/mL) and a decrease of more than 20% over time were more reliable indicators of impending kidney complications than other measures like NT-proBNP or SGLT2 inhibitor use.